Technology
Health
Pharmaceutical

Citius Pharmaceuticals

$1.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.16 (12.50%) Today
+$0.16 (11.11%) After Hours

Why Robinhood?

You can buy or sell CTXR and other stocks, options, ETFs, and crypto commission-free!

About

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. Read More The company was founded by Ralph Montrone on September 9, 2010 and is headquartered in Cranford, NJ.

Employees
7
Headquarters
Cranford, New Jersey
Founded
2010
Market Cap
22.78M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
116.39K
High Today
$1.47
Low Today
$1.33
Open Price
$1.33
Volume
91.47K
52 Week High
$3.25
52 Week Low
$0.8582

Collections

Technology
Health
Pharmaceutical
2017 IPO
US
North America

News

MarketBeatMar 1

Stock Price, News, & Analysis for Citius Pharmaceuticals

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of h...

207
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.